Summary of Vascular Anomalies: Classification, Diagnosis, and Management
Vascular Anomalies: Classification, Diagnosis, Management
Introduction
Vascular malformations are congenital abnormalities of the vascular system that may require intervention when symptomatic. This material focuses on management strategies, procedural choices, expected outcomes, and complications for lesions that are treated by sclerotherapy and surgical resection. It synthesizes practical guidance, decision-making principles, and examples to help you plan and counsel patients.
Definition: Vascular malformation management encompasses nonoperative and operative interventions aimed at reducing symptoms, preventing complications, and improving function or cosmesis for vascular malformations.
Overview of treatment approaches
Treatment is tailored to lesion type, size, location, symptoms, and prior therapy. Major options include:
- Sclerotherapy — injection of a sclerosant into lesion spaces to induce inflammation and fibrosis, collapsing channels or cysts.
- Surgical resection — partial or complete excision of malformation tissue.
- Ablative techniques (e.g., radiofrequency, CO2 laser) — for surface vesicles or localized mucosal disease.
When to prefer sclerotherapy
- First-line for many cystic or compressible lesions that can be accessed percutaneously.
- Lower overall complication rate compared with attempted open resection when applicable.
- Often used repeatedly over the patient’s lifetime because lesions can re-expand.
Definition: Sclerotherapy is the percutaneous aspiration of cystic spaces followed by injection of an inflammatory agent to scar cyst walls together, reducing lesion volume.
Common sclerosants and their characteristics
| Sclerosant | Typical use | Efficacy / notes | Major risks |
|---|---|---|---|
| Doxycycline | Preferred for many lymphatic-type macrocysts | ~83% size reduction reported; low skin ulceration risk (<5%) | Low systemic toxicity; local pain/irritation |
| Sodium tetradecyl sulfate (STS) | Second-line agent | Effective in many cases | Risk of cutaneous ulceration |
| Ethanol | Potent sclerosant for small lesions | High efficacy but high complication rate | Nerve injury, CNS depression, pulmonary hypertension, hemolysis, thromboembolism, arrhythmias |
| Bleomycin | Used in some centers | Effective for microcystic disease | Risk of pulmonary toxicity if high systemic exposure |
| OK-432 | Immunostimulatory agent used in some regions | Variable availability; recurrence reported | Generally limited by access |
Practical considerations for sclerosant selection
- Prefer doxycycline when effective and available because of favorable safety and efficacy.
- Use STS when doxycycline is unsuitable or unavailable.
- Reserve ethanol for small, well-localized lesions where its potency is needed; avoid large-volume injections and proximity to critical nerves.
- Avoid agents that are not accessible regionally (e.g., OK-432 in some areas).
Complications of sclerotherapy
- Most common: cutaneous ulceration (<5% overall for lymphatic-type lesions with common sclerosants).
- Agent-specific systemic toxicity (notably with ethanol): CNS depression, pulmonary hypertension, hemolysis, thromboembolism, arrhythmias.
- Extravasation into muscle can lead to atrophy and contracture.
- Lesions frequently re-expand over time; expect need for repeat procedures (for example, ~9% recur within 3 years after OK-432 and more with longer follow-up).
Surgical resection: indications, technique, and risks
Surgery is reserved for situations where sclerotherapy is ineffective or not feasible, or for specific symptomatic problems.
Indications for resection
- Symptomatic microcystic disease causing bleeding, infection, or deformity that cannot be controlled otherwise.
- Symptomatic macro- or combined lesions that have exhausted sclerotherapy options (e.g., no macrocysts rema
Sign up for the full summaryAlready have an account? Sign in
Vascular Malformations Management
Klíčová slova: Vascular anomalies overview, Vascular anomalies: hemangiomas, Infantile hemangioma diagnosis & pathology, Infantile hemangioma management & treatment, Vascular tumors, Capillary malformation, Lymphatic malformation, Vascular Malformations Management, Venous malformation, Arteriovenous malformation, Vascular anomalies: malformations, PTEN-associated vascular anomaly
Klíčové pojmy: Prefer doxycycline sclerotherapy for macrocystic lesions due to ~83% size reduction and low ulceration risk, Use STS as second-line sclerosant when doxycycline is unsuitable, Reserve ethanol for small, well-localized lesions due to high systemic and neural toxicity, Most common sclerotherapy complication is cutaneous ulceration (<5%), Expect lesion re-expansion; plan for repeat sclerotherapy over a patient’s lifetime, Reserve resection for symptomatic microcystic disease, failed sclerotherapy, or small well-localized lesions, Favor subtotal or staged resections for diffuse disease to minimize deformity and morbidity, Counsel patients about trade-offs: multiple minimally invasive sessions versus higher-risk surgery with potential deformity, Avoid ethanol near critical nerves to prevent nerve injury, Use radiofrequency ablation or CO2 laser for mucosal/microcystic surface vesicles when appropriate, Weigh postoperative scar against preoperative appearance when planning resection, For cervicofacial resections, explicitly discuss high risk of facial or hypoglossal nerve injury